Regenxbio (RGNX) EBIT Margin (2014 - 2026)
Regenxbio (RGNX) posted EBIT Margin of 27.09% for Q2 2026, up 323.35 percentage points from -296.26% a year earlier.
Powered by 
Analysis
Regenxbio (RGNX) EBIT Margin (2014 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, EBIT Margin at Regenxbio was -76.04%, up 29.62 percentage points year-over-year; for FY2025, it was -94.58%, up 185.46 percentage points from FY2024.
- Annual EBIT Margin shows a five-year change of -17.44 percentage points (FY2020 to FY2025).
- In prior years, Regenxbio's EBIT Margin was -280.03% in FY2024 (+17.09 pp), -297.12% in FY2023 (-63.92 pp), -233.20% in FY2022 (-267.22 pp) and 34.01% in FY2021 (+111.15 pp).
- The Q2 2026 figure stands as the highest quarterly EBIT Margin since Q4 2021.
- On a year-over-year basis, EBIT Margin increased in five of the last seven quarters, with an average year-over-year change of +120.99 percentage points.
- The strongest year-over-year quarter for EBIT Margin in the past five years was Q1 2025, with a gain of 422.43 percentage points; the weakest was Q4 2022, with a drop of 262.97 percentage points.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 28.37% |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn | 37.40% |
| 10 | Regenxbio | 403.52 Mn | -529.57 Mn | - | 27.09% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27.09% |
| Dec 31, 2025 | -189.99% |
| Sep 30, 2025 | -176.27% |
| Jun 30, 2025 | -296.26% |
| Mar 31, 2025 | 13.62% |
| Dec 31, 2024 | -242.14% |
| Sep 30, 2024 | -256.55% |
| Jun 30, 2024 | -251.34% |
| Mar 31, 2024 | -408.80% |
| Dec 31, 2023 | -287.68% |
| Sep 30, 2023 | -224.67% |
| Jun 30, 2023 | -365.96% |
| Mar 31, 2023 | -345.68% |
| Dec 31, 2022 | -184.31% |
| Sep 30, 2022 | -267.97% |
| Jun 30, 2022 | -191.53% |
| Mar 31, 2022 | -321.93% |
| Dec 31, 2021 | 78.66% |
| Sep 30, 2021 | -186.36% |
| Jun 30, 2021 | -237.01% |
API Access
Regenxbio EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=RGNX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "RGNX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=RGNX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();